vandetanib + selumetinib

Vandetanib + selumetinib is an investigational oral combination therapy of two small molecule inhibitors developed for the treatment of solid tumors, including non-small cell lung cancer (NSCLC). Vandetanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET tyrosine kinases. Selumetinib is a MEK inhibitor targeting the mitogen-activated protein kinase pathway. The rationale for combining these agents is to simultaneously inhibit multiple signaling pathways involved in tumor cell proliferation and survival. Phase I studies have shown that the combination can be administered with manageable toxicity, with dose-limiting toxicities primarily related to known side effects of each agent. The combination has demonstrated stable disease in some NSCLC patients but further efficacy data are limited[1][2][3][4][5].

Other names

VanSel-1VanSel1VanSel 1